Biotech Today
  • Privacy Policy
  • Disclaimer
  • Biotech
  • Markets
  • Bio Space
  • Global News

All Posts in "Biotechnology Today"

CubeSmart (CUBE) Moves Higher on Volume Spike for December 06

CubeSmart (CUBE) Moves Higher on Volume Spike for December 06

CubeSmart (CUBE) traded on unusually high volume on Dec. 06, as the stock gained 3.09% to close at $32.39. On the day, CubeSmart saw 2.2 million shares trade hands on 16,887 trades. Considering that the stock averages only a daily volume of 1.44 million shares a day over the last month, this represents a pretty significant bump in volume over the norm.

News Team by News Team — December 07, 2018 By News Team in Biotechnology Today
KAI’s swap deal with Spain a win-win

KAI’s swap deal with Spain a win-win

Korea Aerospace Industries and Spanish government’s swap deal will be a win-win for both parties, said BNK Investment and Securities on Dec. 6 maintaining a “buy” recommendation and 47,000 won (US$42.10) target price.

News Team by News Team — December 06, 2018 By News Team in Biotechnology Today
JSE falls 1% after US equities tumble

JSE falls 1% after US equities tumble

The JSE took its cue from a global equity sell-off on Wednesday with broad-based losses, as investor concern about the pause in the US-China trade war continues to elicit caution.

News Team by News Team — December 06, 2018 By News Team in Biotechnology Today
Samsung Electro-Mechanics long-term outlook good

Samsung Electro-Mechanics long-term outlook good

Although Samsung Electro-Mechanics is facing price pressure in the MLCC sector it has a positive outlook in the long term, said NH Investment and Securities on Dec. 6 maintaining a “buy” recommendation and 210,000 won (US$188.14) target price.

News Team by News Team — December 06, 2018 By News Team in Biotechnology Today
Oil rallies while equities remain weak

Oil rallies while equities remain weak

Heading into the close, the FTSE 100 is down 80 points, as markets continue to fret about growth and trade wars.

News Team by News Team — December 06, 2018 By News Team in Biotechnology Today
U.K. funds continue move out of equities, ‘Purple Book’ shows

U.K. funds continue move out of equities, ‘Purple Book’ shows

UK. corporate defined benefit pension funds continued to divest from equities in favor of bonds, show data in the Pensions Universe Risk Profile — known as “The Purple Book.”

News Team by News Team — December 05, 2018 By News Team in Biotechnology Today
SK hynix faces fast-descending industry

SK hynix faces fast-descending industry

SK hynix will have to deal with the semiconductor industry’s faster-than-expected decline, said HI Investment and Securities on Dec. 5 while maintaining a “hold” recommendation and 70,000 won (US$62.98) target price.

News Team by News Team — December 05, 2018 By News Team in Biotechnology Today
Albemarle Corporation (ALB) Dips 5.35% for December 04

Albemarle Corporation (ALB) Dips 5.35% for December 04

Among the S&P 500’s biggest fallers on Tuesday December 04 was Albemarle Corporation (ALB). The stock experienced a 5.35% decline to $93.19 with 2.42 million shares changing hands.

News Team by News Team — December 05, 2018 By News Team in Biotechnology Today
Allstate Corporation (The) (ALL) Dips 2.66% for December 04

Allstate Corporation (The) (ALL) Dips 2.66% for December 04

Among the S&P 500’s biggest fallers on Tuesday December 04 was Allstate Corporation (The) (ALL). The stock experienced a 2.66% decline to $86.40 with 2.7 million shares changing hands.

News Team by News Team — December 05, 2018 By News Team in Biotechnology Today
LG Innotek’s earnings outlook negative

LG Innotek’s earnings outlook negative

LG Innotek’s earnings from the fourth quarter will decline as its major client Apple faces slower-than-expected sales, said Hana Financial Investment on Dec. 4 lowering the target price to 150,000 won (US$134.89) from 140,000 won.

News Team by News Team — December 04, 2018 By News Team in Biotechnology Today

Posts pagination

Previous 1 … 674 675 676 … 712 Next
  • Psychosis patients ‘living in metaphor’: New study radically shifts ideas about delusionsPsychosis patients ‘living in metaphor’: New study radically shifts ideas about delusions
  • Most COVID-19 vaccine hesitancy linked to concerns that can be overcome, study suggestsMost COVID-19 vaccine hesitancy linked to concerns that can be overcome, study suggests
  • Gamma rays quickly toughen nitrogen‑fixing bacteriaGamma rays quickly toughen nitrogen‑fixing bacteria
  • Designer enzyme enables yeast to produce custom fatty acids, reducing need for palm oilDesigner enzyme enables yeast to produce custom fatty acids, reducing need for palm oil
  • AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific MarketAbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
  • At JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the SunAt JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the Sun
  • How weight loss benefits the health of your fat tissueHow weight loss benefits the health of your fat tissue
  • Like alcohol units, but for cannabis—experts define safer limitsLike alcohol units, but for cannabis—experts define safer limits
  • A new AI tool could dramatically speed up the discovery of life-saving medicinesA new AI tool could dramatically speed up the discovery of life-saving medicines
  • Commercially viable biomanufacturing: Designer yeast turns sugar into lucrative chemical 3-HPCommercially viable biomanufacturing: Designer yeast turns sugar into lucrative chemical 3-HP

Newsletter

Advertisement

Market Data by TradingView

Popular Posts

  • Most COVID-19 vaccine hesitancy linked to concerns that can be overcome, study suggestsMost COVID-19 vaccine hesitancy linked to concerns that can be overcome, study suggests
  • All Orchard Supply Stores To CloseAll Orchard Supply Stores To Close
  • The Echo Dot for cars is on sale for just $48 right nowThe Echo Dot for cars is on sale for just $48 right now
  • Market milestone: This is the longest bull run in historyMarket milestone: This is the longest bull run in history

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. biotech-today.com is a wholly-owned subsidiary of Maynard Communication Limited.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

ABOUT US

Biotech Todayr

    Biotech Today shares news and information from biotechnology space. We focus on news, trending companies, leading technology, breakthroughs, and breaking topics as they happen.

Trending Now

  • Vaccine Breakthroughs Stemming from 2020 Crisis Could Treat MORE Than Just Covid-19, Creating Major Opportunity for InvestorsVaccine Breakthroughs Stemming from 2020 Crisis Could Treat MORE Than Just Covid-19, Creating Major Opportunity for Investors
  • QuestCap Inc. – The Social Impact Investment Company Targeting Pandemic Response Technologies and TherapiesQuestCap Inc. – The Social Impact Investment Company Targeting Pandemic Response Technologies and Therapies
  • Is This A Digital HealthTech Giant In The Making?

Subscribe and Follow

Contact Us

    • Biotech Today

 

  • info@maynardcom.com
  • www.biotech-today.com
© 2023 Biotech-Today.com All Rights Reserved | Privacy Policy
Scroll Up